Bellon Christine 4
4 · Beam Therapeutics Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Bellon Christine
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-14$7.22/sh+9,492$68,532→ 112,460 total - Exercise/Conversion
Common Stock
2025-02-14$7.22/sh+508$3,668→ 112,968 total - Sale
Common Stock
2025-02-14$34.00/sh−10,000$340,000→ 102,968 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-14−9,492→ 0 totalExercise: $7.22Exp: 2029-05-16→ Common Stock (9,492 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-14−508→ 10,410 totalExercise: $7.22Exp: 2029-05-17→ Common Stock (508 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2024.
- [F2]The option vested as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option was fully vested.
- [F3]The option vested as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option was fully vested.